An FDA panel of health experts voted to support approval for mass production of Genzyme's Myozyme for the treatment of Pompe disease, a rare muscle disorder that can lead to fatal respiratory ...

Genzyme Corp <GENZ.O> said on Monday U.S. regulators asked the company to submit a new drug application before it can market a larger-scale version of Pompe disease treatment Myozyme, which will ...

SAN FRANCISCO (MarketWatch) -- Genzyme Corp. said Thursday that it has initiated a clinical trial evaluating the safety and efficacy of Myozyme in patients with late-onset Pompe disease, a ...

Sanofi is developing a new experimental enzyme-replacement therapy that could succeed Myozyme as a treatment for Pompe disease, part of the drugmaker’s plan to bolster the product pipeline of ...

Firm is also expanding capacity at its current plant. Genzyme will build a €250 million manufacturing plant in Geel, Belgium, for its Pompe disease therapies, Myozyme® and Lumizyme®.

BOSTON, Feb 26 (Reuters) - Genzyme Corp said on Thursday it has won European approval to make its drug Myozyme at a 4,000-liter manufacturing facility, expanding supply for patients with the rare ...